The recent news of risky investment portfolios, oil spills and contaminated drug products highlight the magnitude of risks that businesses face and the devastating consequences if they are not visible or well managed. But, whose job is it to manage risk and how well is this effort being performed?
Archive for July, 2010
CFO’s On-point for Managing Risk in Life Sciences
Tuesday, July 27th, 2010Ensuring Launch Success through Supply Chain Readiness
Tuesday, July 20th, 2010Organizations and their supply chains that are preparing to launch a new compound (chemical or biologic) are often physically prepared to support the launch but are often relying on many non-supply related functional groups to provide key information and support. This puts both the plans and launch success at risk.
Buying into a new model – Lilly’s Alnara Acquisition
Monday, July 12th, 2010One hallmark of our industry is the incredible risks faced in bringing a new product to market. New technologies bring risks of not performing the way we’d like. Clinical and regulatory risks can delay or prevent approval. Commercial and market risks may limit success with physicians, patients and customers. All of this leads to huge financial risks for investors along the way, and we have seen this scenario play out repeatedly here in the local area in disappointing results for companies like Therion, Vion, and Acusphere.
(more…)
